Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif– as potential therapeutic agents in the prevention of cardiovascular diseases
Small drug-like molecules that can block the function of serotonin 5-HT2A receptors have garnered considerable attention due to their ability to inhibit platelet aggregation and the possible prevention of atherosclerotic lesions. Although clinical data provided compelling evidence for the efficacy o...
Guardado en:
Autores principales: | Monika Marcinkowska, Monika Kubacka, Agnieszka Zagorska, Anna Jaromin, Nikola Fajkis-Zajaczkowska, Marcin Kolaczkowski |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0bb8cee8aad04c15b6bfe085a004d6ad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Synthesis, chemo-informatics, and anticancer evaluation of fluorophenyl-isoxazole derivatives
por: Hawash Mohammed, et al.
Publicado: (2021) -
A Facile Approach to Bis(isoxazoles), Promising Ligands of the AMPA Receptor
por: Dmitry A. Vasilenko, et al.
Publicado: (2021) -
ANTIPLATELET AGENTS IN THE TREATMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
por: E. Y. Kitaeva, et al.
Publicado: (2017) -
Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock
por: Wiktor Kuliczkowski, et al.
Publicado: (2020) -
Early Surgery with Neuraxial Anaesthesia in Patients on Chronic Antiplatelet Therapy with a Proximal Femur Fracture: Multicentric Randomised Clinical Trial
por: Rafael Anaya, et al.
Publicado: (2021)